U.S. markets close in 4 hours 10 minutes

Celltrion, Inc. (068270.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
175,500.00+4,500.00 (+2.63%)
At close: 03:30PM KST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close171,000.00
Bid176,500.00 x 0
Ask177,000.00 x 0
Day's Range169,500.00 - 179,000.00
52 Week Range139,000.00 - 253,431.38
Avg. Volume387,610
Market Cap24.265T
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & Yield750.00 (0.45%)
Ex-Dividend DateDec 29, 2021
1y Target Est230,846.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 068270.KS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Bloomberg

      After 1,200% Rally, Korea’s Star Tech Stocks Need Staying Power

      (Bloomberg) -- For equity investors in South Korea, this was the year the metaverse arrived.Most Read from BloombergOmicron Cases Are Hitting Highs, But New Data Put End in SightU.S. Logs Record 1 Million Virus Cases With Data DelayPolice Pinpoint Starting Point of Historic Colorado WildfireIvanka Trump, Donald Trump Jr. Subpoenaed in Asset ProbeU.S. Catches Kremlin Insider Who May Have Secrets of 2016 HackSix of the nation’s 10 best-performing stocks in 2021 are linked to the virtual universe o

    • Reuters

      UPDATE 2-EU regulator backs COVID-19 drugs from Regeneron-Roche, Celltrion

      Europe's drug regulator has recommended two COVID-19 antibody therapies - one from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defence against surging cases. Approval by the European Commission would mark the first for any COVID-19 treatment on the continent since Gilead's remdesivir last year Reuters reported earlier this week that the European Medicines Agency's (EMA) endorsement of the two drugs was imminent.